These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25978789)

  • 1. Cognitive improvements in a mouse model with substituted 1,2,3-triazole agonists for nicotinic acetylcholine receptors.
    Arunrungvichian K; Boonyarat C; Fokin VV; Taylor P; Vajragupta O
    ACS Chem Neurosci; 2015 Aug; 6(8):1331-40. PubMed ID: 25978789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive improvements in a rat model with polyunsaturated fatty acids EPA and DHA through α7-nicotinic acetylcholine receptors.
    Carlos DH; Bibiana Roselly CR; Angel UL; Laura MA; Kenya Karina SR; Jose Manuel CB; Alejandra CS; Gabriela CCE; Estefanía OR; Aracely SM
    Nutr Neurosci; 2022 Apr; 25(4):791-800. PubMed ID: 32840165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition.
    Miyauchi M; Neugebauer NM; Oyamada Y; Meltzer HY
    Behav Brain Res; 2016 Mar; 301():204-12. PubMed ID: 26519556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
    Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
    J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity optimization of substituted 1,2,3-triazoles as α7 nicotinic acetylcholine receptor agonists.
    Arunrungvichian K; Fokin VV; Vajragupta O; Taylor P
    ACS Chem Neurosci; 2015 Aug; 6(8):1317-30. PubMed ID: 25932897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
    Sadigh-Eteghad S; Talebi M; Mahmoudi J; Babri S; Shanehbandi D
    Neuroscience; 2015 Jul; 298():81-93. PubMed ID: 25881725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral effects of PNU-282987, an alpha7 nicotinic receptor agonist, in mice.
    Vicens P; Ribes D; Torrente M; Domingo JL
    Behav Brain Res; 2011 Jan; 216(1):341-8. PubMed ID: 20728474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the α7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT₁a receptor antagonist.
    Pandya AA; Yakel JL
    Neuropharmacology; 2013 Jul; 70():35-42. PubMed ID: 23321689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations.
    Stoiljkovic M; Kelley C; Nagy D; Leventhal L; Hajós M
    Neuropharmacology; 2016 Nov; 110(Pt A):102-108. PubMed ID: 27422408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.
    Van Kampen M; Selbach K; Schneider R; Schiegel E; Boess F; Schreiber R
    Psychopharmacology (Berl); 2004 Apr; 172(4):375-83. PubMed ID: 14727003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
    Prickaerts J; van Goethem NP; Chesworth R; Shapiro G; Boess FG; Methfessel C; Reneerkens OA; Flood DG; Hilt D; Gawryl M; Bertrand S; Bertrand D; König G
    Neuropharmacology; 2012 Feb; 62(2):1099-110. PubMed ID: 22085888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Furan-2-yl-N-p-tolyl-acrylamide, a highly selective positive allosteric modulator of α7 nicotinic receptors, produces anxiolytic-like activity in mice.
    Targowska-Duda KM; Budzynska B; Michalak A; Jozwiak K; Biala G; Arias HR
    J Psychopharmacol; 2019 May; 33(5):558-567. PubMed ID: 30644335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders.
    McLean SL; Grayson B; Marsh S; Zarroug SH; Harte MK; Neill JC
    Behav Brain Res; 2016 Apr; 302():73-80. PubMed ID: 26327238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of α7 Nicotinic Acetylcholine Receptor by its Selective Agonist Improved Learning and Memory of Amyloid Precursor Protein/Presenilin 1 (APP/PS1) Mice via the Nrf2/HO-1 Pathway.
    Cao K; Xiang J; Dong YT; Xu Y; Guan ZZ
    Med Sci Monit; 2022 Jan; 28():e933978. PubMed ID: 34980874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.
    Marighetto A; Valerio S; Desmedt A; Philippin JN; Trocmé-Thibierge C; Morain P
    Psychopharmacology (Berl); 2008 Apr; 197(3):499-508. PubMed ID: 18265960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
    Wishka DG; Walker DP; Yates KM; Reitz SC; Jia S; Myers JK; Olson KL; Jacobsen EJ; Wolfe ML; Groppi VE; Hanchar AJ; Thornburgh BA; Cortes-Burgos LA; Wong EH; Staton BA; Raub TJ; Higdon NR; Wall TM; Hurst RS; Walters RR; Hoffmann WE; Hajos M; Franklin S; Carey G; Gold LH; Cook KK; Sands SB; Zhao SX; Soglia JR; Kalgutkar AS; Arneric SP; Rogers BN
    J Med Chem; 2006 Jul; 49(14):4425-36. PubMed ID: 16821801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of multifunctional ligands targeting acetylcholinesterase and alpha 7 nicotinic acetylcholine receptor.
    Cieslikiewicz-Bouet M; Naldi M; Bartolini M; Pérez B; Servent D; Jean L; Aráoz R; Renard PY
    Biochem Pharmacol; 2020 Jul; 177():114010. PubMed ID: 32360492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function.
    Sadigh-Eteghad S; Mahmoudi J; Babri S; Talebi M
    Acta Cir Bras; 2015 Nov; 30(11):736-42. PubMed ID: 26647792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.
    Boess FG; de Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; König G
    Psychopharmacology (Berl); 2013 May; 227(1):1-17. PubMed ID: 23241647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.